BridgeBio Pharma, Inc. — Director's Dealing 2020

Jul 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-07-01

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-01	Common Stock	M	10000	$0.16	Acquired	270293	Direct
2020-07-01	Common Stock	S	7168	$30.6277	Disposed	263125	Direct
2020-07-01	Common Stock	S	2632	$31.7739	Disposed	260493	Direct
2020-07-01	Common Stock	S	200	$32.665	Disposed	260293	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-01	Stock Option (Right to Buy)	$0.16	M	10000	Disposed	2028-08-26	Common Stock (10000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.

F2: Represents the weighted average sale price of the shares sold from $30.13 to $31.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4.

F3: Represents the weighted average sale price of the shares sold from $31.28 to $32.17 per share.

F4: Represents the weighted average sale price of the shares sold from $32.56 to $32.77 per share.